BR112022013628A2 - Métodos para tratar doenças inflamatórias intestinais com antagonistas de integrina alpha-4 beta-7 - Google Patents
Métodos para tratar doenças inflamatórias intestinais com antagonistas de integrina alpha-4 beta-7Info
- Publication number
- BR112022013628A2 BR112022013628A2 BR112022013628A BR112022013628A BR112022013628A2 BR 112022013628 A2 BR112022013628 A2 BR 112022013628A2 BR 112022013628 A BR112022013628 A BR 112022013628A BR 112022013628 A BR112022013628 A BR 112022013628A BR 112022013628 A2 BR112022013628 A2 BR 112022013628A2
- Authority
- BR
- Brazil
- Prior art keywords
- inflammatory bowel
- methods
- bowel diseases
- treatment
- antagonists
- Prior art date
Links
- 208000022559 Inflammatory bowel disease Diseases 0.000 title abstract 5
- 239000005557 antagonist Substances 0.000 title abstract 4
- 108010043603 integrin alpha4beta7 Proteins 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 239000000539 dimer Substances 0.000 abstract 2
- 102000006495 integrins Human genes 0.000 abstract 2
- 108010044426 integrins Proteins 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 229940122065 Alpha4beta7 integrin antagonist Drugs 0.000 abstract 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
MÉTODOS PARA TRATAR DOENÇAS INFLAMATÓRIAS INTESTINAIS COM ANTAGONISTAS DE INTEGRINA a4ß7. A invenção se refere a métodos de tratamento de doenças inflamatórias intestinais, incluindo com peptídeos engenheirados (por exemplo, monômeros e dímeros peptídicos compreendendo ligações intramoleculares dissulfeto ou tioéter) que ligam à integrina a4ß7. Em um aspecto, a divulgação fornece um método de tratamento de uma doença inflamatória intestinal (IBD) em um sujeito em necessidade do mesmo compreendendo administrar ao sujeito um antagonista de integrina a4ß7, em que o antagonista é administrado ao paciente oralmente a uma dose de cerca de 100 mg a cerca de 500 mg, uma ou duas vezes ao dia, em que o antagonista é um composto de dímero peptídico compreendendo dois peptídeos ou um sal farmaceuticamente aceitável do mesmo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062959854P | 2020-01-10 | 2020-01-10 | |
| PCT/US2021/012842 WO2021142373A1 (en) | 2020-01-10 | 2021-01-08 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES WITH α4β7 INTEGRIN ANTAGONISTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022013628A2 true BR112022013628A2 (pt) | 2022-11-22 |
Family
ID=76788328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022013628A BR112022013628A2 (pt) | 2020-01-10 | 2021-01-08 | Métodos para tratar doenças inflamatórias intestinais com antagonistas de integrina alpha-4 beta-7 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230063321A1 (pt) |
| EP (1) | EP4093421A4 (pt) |
| JP (1) | JP2023509790A (pt) |
| KR (1) | KR20220125268A (pt) |
| CN (1) | CN115038457A (pt) |
| AU (1) | AU2021205415A1 (pt) |
| BR (1) | BR112022013628A2 (pt) |
| CA (1) | CA3166637A1 (pt) |
| IL (1) | IL294580A (pt) |
| MX (1) | MX2022008486A (pt) |
| WO (1) | WO2021142373A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| DK3143037T3 (da) | 2014-05-16 | 2021-09-20 | Protagonist Therapeutics Inc | Alpha4beta7-integrin-thioether-peptidantagonister |
| RU2736637C9 (ru) | 2014-07-17 | 2021-02-08 | Протагонист Терепьютикс, Инк. | Пептидные ингибиторы рецептора интерлейкина-23 для перорального приема и их применение для лечения воспалительных заболеваний кишечника |
| WO2019157268A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| CN118005737A (zh) | 2020-01-15 | 2024-05-10 | 詹森生物科技公司 | 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途 |
| CA3202226A1 (en) | 2020-11-20 | 2022-05-27 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2691113A4 (en) * | 2011-03-31 | 2014-12-24 | Hoffmann La Roche | METHODS OF ADMINISTERING BETA7 INTEGRIN ANTAGONISTS |
| EP3492099A1 (en) * | 2011-11-23 | 2019-06-05 | Amgen Inc. | Administration of alpha4beta7 hetero-dimer-specific antibody |
| DK3143037T3 (da) * | 2014-05-16 | 2021-09-20 | Protagonist Therapeutics Inc | Alpha4beta7-integrin-thioether-peptidantagonister |
| JP2017535527A (ja) * | 2014-10-01 | 2017-11-30 | プロタゴニスト セラピューティクス， インコーポレイテッド | 新規のα４β７ペプチド単量体及び二量体拮抗薬 |
| US11286281B2 (en) * | 2017-05-10 | 2022-03-29 | Zealand Pharma A/S | Homodetic cyclic peptides targeting alpha-4-beta-7 integrin |
-
2021
- 2021-01-08 KR KR1020227025943A patent/KR20220125268A/ko unknown
- 2021-01-08 WO PCT/US2021/012842 patent/WO2021142373A1/en unknown
- 2021-01-08 CN CN202180012070.7A patent/CN115038457A/zh active Pending
- 2021-01-08 MX MX2022008486A patent/MX2022008486A/es unknown
- 2021-01-08 EP EP21738981.6A patent/EP4093421A4/en active Pending
- 2021-01-08 BR BR112022013628A patent/BR112022013628A2/pt not_active Application Discontinuation
- 2021-01-08 US US17/788,179 patent/US20230063321A1/en active Pending
- 2021-01-08 CA CA3166637A patent/CA3166637A1/en active Pending
- 2021-01-08 JP JP2022542360A patent/JP2023509790A/ja active Pending
- 2021-01-08 AU AU2021205415A patent/AU2021205415A1/en active Pending
-
2022
- 2022-07-07 IL IL294580A patent/IL294580A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021205415A8 (en) | 2023-08-10 |
| EP4093421A4 (en) | 2024-01-10 |
| JP2023509790A (ja) | 2023-03-09 |
| IL294580A (en) | 2022-09-01 |
| EP4093421A1 (en) | 2022-11-30 |
| US20230063321A1 (en) | 2023-03-02 |
| WO2021142373A1 (en) | 2021-07-15 |
| KR20220125268A (ko) | 2022-09-14 |
| MX2022008486A (es) | 2022-10-13 |
| CA3166637A1 (en) | 2021-07-15 |
| CN115038457A (zh) | 2022-09-09 |
| AU2021205415A1 (en) | 2022-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022013628A2 (pt) | Métodos para tratar doenças inflamatórias intestinais com antagonistas de integrina alpha-4 beta-7 | |
| JP2022037132A (ja) | 筋萎縮性側索硬化症患者の下位集団の治療のためのマシチニブの使用 | |
| Distler et al. | RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis | |
| CN105228622B (zh) | 用于治疗多发性硬化的PPARγ激动剂 | |
| AU2017281980B2 (en) | Wnt inhibitors for use in the treatment of fibrosis | |
| EP3185881A2 (en) | Methods, agents and compositions for treatment of inflammatory conditions | |
| US20190091252A1 (en) | Pharmaceutical compositions for the treatment of cancer | |
| Lv et al. | Thymosin‑β 4 induces angiogenesis in critical limb ischemia mice via regulating Notch/NF‑κB pathway | |
| JP7075136B2 (ja) | 整形外科疾患の治療のための組成物および方法 | |
| WO2021202546A8 (en) | Early drug interventions to reduce covid-19 related respiratory distress, need for ventilator assistance and death | |
| CL2021003312A1 (es) | Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma. | |
| BR112022008095A2 (pt) | Métodos e composições para o tratamento da síndrome de rett | |
| BR112022026999A2 (pt) | Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas | |
| Maki et al. | Symmetrical skin lesions on the gluteal region in a patient with anti-laminin-332 mucous membrane pemphigoid | |
| RU2774830C1 (ru) | Способ ранней диагностики воспаления плечевого сустава у собак | |
| WO2020211772A1 (en) | Purmorphamine as a small compound positive allosteric modulator of secretin receptor for the treatment of hypertension | |
| IT201800006455A1 (it) | Nuovo utilizzo degli inibitori della monoammino ossidasi B | |
| WO2022004788A1 (ja) | 代謝異常を伴う疾患又は症候群における筋力低下症状の改善剤又は予防剤 | |
| Hamoud et al. | Leprotic Arthritis | |
| Bakı et al. | Applicatıon of femoral+ sciatic block in high risk patients: Two cases | |
| Chou et al. | Rabbit spinal cord ischemia model for the development of neuroprotective treatments | |
| Bałkowiec-Iskra et al. | Venous thromboembolism as an adverse effect of antipsychotic treatment | |
| JPH02115122A (ja) | 慢性関節リウマチ治療剤 | |
| EP2767287B1 (en) | Agent for preventing or treating htlv-i associated myelopathy | |
| Ridwan et al. | Case Series of Guillain Barre Syndrome with Plasmaparesis in The ICU Bandung Hospital |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |